Cargando…

Liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis

Idiopathic pulmonary hemosiderosis (IPH) is a rare disease in children, with unknown etiology. The classical clinical triad is hemoptysis, hypochromic anemia and diffuse parenchymal infiltrations on chest X-ray. Liposteroid dexamethasone palmitate, which was developed in Japan, has shown good effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Rieko, Matsumoto, Shiro, Mitsubuchi, Hiroshi, Nakamura, Kimitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010611/
https://www.ncbi.nlm.nih.gov/pubmed/29977750
http://dx.doi.org/10.1016/j.rmcr.2018.03.011
_version_ 1783333617236180992
author Sakamoto, Rieko
Matsumoto, Shiro
Mitsubuchi, Hiroshi
Nakamura, Kimitoshi
author_facet Sakamoto, Rieko
Matsumoto, Shiro
Mitsubuchi, Hiroshi
Nakamura, Kimitoshi
author_sort Sakamoto, Rieko
collection PubMed
description Idiopathic pulmonary hemosiderosis (IPH) is a rare disease in children, with unknown etiology. The classical clinical triad is hemoptysis, hypochromic anemia and diffuse parenchymal infiltrations on chest X-ray. Liposteroid dexamethasone palmitate, which was developed in Japan, has shown good efficacy for IPH. We present the case of a patient with IPH, who suffered from a life-threatening respiratory dysfunction, and was rescued by a trial administration of liposteroid with methylprednisolone (mPSL). A 6-year-old girl was admitted to our hospital for repeated dyspnea and blood-stained sputum. She was diagnosed with IPH at the age of three-months by iron staining of gastric fluid and sputum studies. Her cumulative dose of steroids (equivalent to prednisolone (PSL)) was 1062 mg/kg. However, she could not achieve remission. We decided to initiate liposteroid therapy. We administered an infusion of liposteroid 0.8 mg/kg intravenously, for three consecutive days as a therapy for acute bleeding. After administration of liposteroid, she developed high fever with CRP elevation. We suspected that the inflammation was caused by palmitate, which is present as a lipo base in liposteroid. Hence, we added 2 mg/kg mPSL per day for 1 week. As a maintenance treatment, a single infusion of liposteroid was administered followed by mPSL administration for 6 days in every week. Her respiratory condition slowly improved. Tracheostomy was performed for airway management. She was shifted out of the ICU on the 34th day. Steroid is a key therapy for hemosiderosis. When IPH is diagnosed, oral prednisone therapy is initiated. Although this is effective, there are limitations due to significant adverse effects. Maintaining drug therapy is very important for IPH patients to keep the disease under control. Liposteroid has the same mechanism of action as dexamethasone. It has a Lipo-base, palmitate, which could induce pro-inflammatory cytokine activation. We used mPSL to inhibit the inflammation following liposteroid administration. This was effective. A combination of liposteroid and mPSL administration was useful method of treatment for the patient.
format Online
Article
Text
id pubmed-6010611
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-60106112018-07-05 Liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis Sakamoto, Rieko Matsumoto, Shiro Mitsubuchi, Hiroshi Nakamura, Kimitoshi Respir Med Case Rep Case Report Idiopathic pulmonary hemosiderosis (IPH) is a rare disease in children, with unknown etiology. The classical clinical triad is hemoptysis, hypochromic anemia and diffuse parenchymal infiltrations on chest X-ray. Liposteroid dexamethasone palmitate, which was developed in Japan, has shown good efficacy for IPH. We present the case of a patient with IPH, who suffered from a life-threatening respiratory dysfunction, and was rescued by a trial administration of liposteroid with methylprednisolone (mPSL). A 6-year-old girl was admitted to our hospital for repeated dyspnea and blood-stained sputum. She was diagnosed with IPH at the age of three-months by iron staining of gastric fluid and sputum studies. Her cumulative dose of steroids (equivalent to prednisolone (PSL)) was 1062 mg/kg. However, she could not achieve remission. We decided to initiate liposteroid therapy. We administered an infusion of liposteroid 0.8 mg/kg intravenously, for three consecutive days as a therapy for acute bleeding. After administration of liposteroid, she developed high fever with CRP elevation. We suspected that the inflammation was caused by palmitate, which is present as a lipo base in liposteroid. Hence, we added 2 mg/kg mPSL per day for 1 week. As a maintenance treatment, a single infusion of liposteroid was administered followed by mPSL administration for 6 days in every week. Her respiratory condition slowly improved. Tracheostomy was performed for airway management. She was shifted out of the ICU on the 34th day. Steroid is a key therapy for hemosiderosis. When IPH is diagnosed, oral prednisone therapy is initiated. Although this is effective, there are limitations due to significant adverse effects. Maintaining drug therapy is very important for IPH patients to keep the disease under control. Liposteroid has the same mechanism of action as dexamethasone. It has a Lipo-base, palmitate, which could induce pro-inflammatory cytokine activation. We used mPSL to inhibit the inflammation following liposteroid administration. This was effective. A combination of liposteroid and mPSL administration was useful method of treatment for the patient. Elsevier 2018-03-20 /pmc/articles/PMC6010611/ /pubmed/29977750 http://dx.doi.org/10.1016/j.rmcr.2018.03.011 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Sakamoto, Rieko
Matsumoto, Shiro
Mitsubuchi, Hiroshi
Nakamura, Kimitoshi
Liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis
title Liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis
title_full Liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis
title_fullStr Liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis
title_full_unstemmed Liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis
title_short Liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis
title_sort liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010611/
https://www.ncbi.nlm.nih.gov/pubmed/29977750
http://dx.doi.org/10.1016/j.rmcr.2018.03.011
work_keys_str_mv AT sakamotorieko liposteroidandmethylprednisolonecombinationtherapyforacaseofidiopathiclunghemosiderosis
AT matsumotoshiro liposteroidandmethylprednisolonecombinationtherapyforacaseofidiopathiclunghemosiderosis
AT mitsubuchihiroshi liposteroidandmethylprednisolonecombinationtherapyforacaseofidiopathiclunghemosiderosis
AT nakamurakimitoshi liposteroidandmethylprednisolonecombinationtherapyforacaseofidiopathiclunghemosiderosis